Get started
Author

Gui‐Ling Chen

Observed names: Chen, Gui-Ling, Gui-Ling Chen
ORCID: 0009-0004-7343-6996
Observed ORCID: 0009-0004-7343-6996
OpenAlex ID: A5000309922
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
2023 · Gui-Ling Chen, Yuan-Zheng Qiu, et al. · Human Vaccines & Immunotherapeutics · 9
PDF
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults
2023 · Gui-Ling Chen, Xu-Ya Yu, et al. · Vaccine · 6
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study
2025 · Zhen‐Wei Shen, Ting‐Han Jin, et al. · Clinical and Translational Science · 4
PDF
QX 008 N , an Anti‐ TSLP Monoclonal Antibody: Pharmacokinetics, Tolerability, and Immunogenicity in Healthy Chinese Subjects
2026 · Zhen‐Wei Shen, Qi Jiang, et al. · Clinical and Translational Science
Author response for "Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study"
2023 · Chen, Gui-Ling, Liu, Yang, et al. · Publons reviews and discussion
Author response for "Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study"
2023 · Chen, Gui-Ling, Liu, Yang, et al. · Publons reviews and discussion
Works count: 6
Citation count: 19
H-index: 3
I10-index:
Year
Topic
Type